Anakinra for neutrophilic pustular skin disease

阿那白滞素（Anakinra）治疗中性粒细胞性脓疱性皮肤病

• 批准号: 8938186
• 负责人: Edward Cowen
• 金额: $ 28.08万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8938186
• 关键词: Clinical; Collaborations; Disease; Enrollment; Goals; Interleukin-1; Laboratories; Outcome; PET/CT scan; Pathway interactions; Patients; Protocols documentation; Pustular psoriasis; Sampling; Serum; Therapeutic; Tissues; Treatment Protocols; anakinra; cardiovascular disorder risk; design; skin disorder

To date, eight patients have enrolled on this treatment protocol. A goal of 25-30 patients has been established to determine if anakinra has efficacy for pustular neurtrophilic skin disease. In addition to the clinical outcomes, tissue and serum samples are being sent to the lab of Raphaela Goldbach-Mansky, Maria Morasso, Alison McBride, and Nehal Mehta in order to further investigate the biologic pathways responsible for pustular psoriasis, including risk of cardiovascular disease as assessed by PET/CT.

迄今为止，已有8名患者接受了这种治疗方案。25-30例患者的目标是确定阿那金对脓疱性嗜神经性皮肤病是否有效。除临床结果外，组织和血清样本将被送往Raphaela Goldbach-Mansky、Maria Morasso、Alison McBride和Nehal Mehta的实验室，以进一步研究脓疱性银屑病的生物学途径，包括通过PET/CT评估的心血管疾病风险。